RecruitingNot ApplicableNCT07329036

ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF

The Artificial Liver Support System (ALSS) in Patients With Acute on Chronic Liver Failure - the Use of Combined Molecular Adsorption System With Double Plasma (DPMAS) and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation and the Function of Vital Organs.

Sponsor

Institute for Clinical and Experimental Medicine

Enrollment

25 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Conditions

Acute Liver Failure

Summary

The artificial liver support system (ALSS) in patients with acute on chronic liver failure - the use of combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE), its effect on primary coagulation, inflammation and the function of vital organs.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria6

Adult patient, age ≥18 years
Expressed consent to the inclusion
Patient hospitalized on ICU with ALF or ACLF diagnosis
Recently meeting the inclusion to liver transplantation
Present on a waiting list to liver transplant
Unsuitable for inclusion to liver transplantation - indicated for support therapy only, but not indented to palliative care

Exclusion Criteria5

Disagreement with the study
Infaust prognosis with expected survival less than 24 hours
Physiologically/biologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA III or IV) or neurological disease, as well as ACLF-3.
Advanced oncological disease (expected life expectancy below 6 months)
Severe degree of Frailty syndrome in secondary severe sarcopenia (muscle and malnutrition) or reduced performance state according

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.